Results from a phase 1b study in psoriasis and two phase 2a studies in ulcerative colitis and rheumatoid arthritis showed that the drug was well-tolerated, and while it showed glimmers of activity in psoriasis missed the mark entirely in the other two indications.
The drug was unable to improve on placebo in the Ladybug study in rheumatoid arthritis, based on the DAS28 symptoms scale, and in the Sea Turtle trial in ulcerative colitis that used the Mayo Clinic Score.
